Tuesday, February 2, 2021

Desperately seeking why India is doing so well with Coronavirus, NPR omits its use of HCQ and ivermectin. Instead, "scientists say it's a mystery"


Last September, India was confirming nearly 100,000 new coronavirus cases a day. It was on track to overtake the United States to become the country with the highest reported COVID-19 caseload in the world. Hospitals were full. The Indian economy nosedived into an unprecedented recession.

But four months later, India's coronavirus numbers have plummeted. Late last month, on Jan. 26, the country's Health Ministry confirmed a record low of about 9,100 new daily cases — in a country of nearly 1.4 billion people. It was India's lowest daily tally in eight months. On Monday, India confirmed about 11,000 cases.
"It's not that India is testing less or things are going underreported," says Jishnu Das, a health economist at Georgetown University. "It's been rising, rising — and now suddenly, it's vanished! I mean, hospital ICU utilization has gone down. Every indicator says the numbers are down.

Scientists say it's a mystery. They're probing why India's coronavirus numbers have declined so dramatically — and so suddenly, in September and October, months before any vaccinations began.  They're trying to figure out what Indians may be doing right and how to mimic that in other countries that are still suffering.

"It's the million-dollar question. Obviously, the classic public health measures are working: Testing has increased, people are going to hospitals earlier and deaths have dropped," says Genevie Fernandes, a public health researcher with the Global Health Governance Programme at the University of Edinburgh. "But it's really still a mystery..."


Anonymous said...

Any comment on those reports of people taking HCQ prophylactic to prevent Covid19? Only to then subsequently in reports infected with Covid19 case in hospitalized iv bamlanivimab or REGN-CoV-2 consists of two antibodies casirivimab and imdevimab?

IV infusion

The German government has now announced it will buy 200,000 doses of bamlanivimab and REGN-CoV-2 for a total cost of €400 million ($485 million), which works out as €2,000 ($2,400) per dose. The drugs will be administered to high-risk patients. Bamlanivimab is a single antibody therapy produced by Eli Lilly. REGN-CoV-2 consists of two antibodies — casirivimab and imdevimab — and has been developed by Regeneron.

Former US President Trump treated with the latter after contracting the coronavirus in October last year. Bamlanivimab and REGN-CoV-2 both received emergency use by the US Food and Drug Administration (FDA) in November 2020. The European Union has yet to greenlight either of the therapies. This particular antibody is made by Eli Lilly. President Trump got a similar medication made by Regeneron — but that product is still under review at the FDA.

Let it spread policies of the President, Kushner’s Cadre offshore tax haven company in Caribbean describes investment opportunities from benefits of coronavirus distressing assets as golden opportunities for Cadre

Kushner’s estimated fortune worth $800 million fortune. The Kushner’s partial offshore tax haven company in the Cayman Islands Cadre holdings worth at least $25 million, nearly 2.5 million shares.



FDA wants to restrict use of the Lilly medicine to people likely to have a 10% of chance of needing hospitalization. In that population, the hospitalization rate would drop to about 3%. So, if the drug is given to 100 people, it could theoretically prevent seven hospitalizations. It basically improves the odds a bit for those eligible to take the drug.

But administering it to people with active coronavirus infections will be a challenge. It needs to be given by IV infusion, which that isn't simple. The treatment is given as a single dose in an infusion that lasts at least an hour, according to drug's instructions. Patients must be monitored for an additional hour.

Variants mean the coronavirus is here to stay
www.washingtonpost.com › health › 2021/02/09

Fourth Wave of COVID-19 Be Prevented? Not Likely, Says Fred Hutch Model —but the Curve Could Be Flattened
Returning to flatten the curve for coming waves

Anonymous said...

Largely because of new variants circulating in the United States. The new variants are the reason why experts believe we will more than likely be living with COVID for years.
“It could possibly linger on for decades maybe even centuries,” Dr. Mark Burns, an infectious disease specialist at UofL Health said.

Doctors have said in the future, we will likely be getting COVID booster shots to deal with the variants. Prevention methods such as masking, distancing, and testing will continue.

This has tremendous implications . in terms of what you can expect with future resurgences of the virus, in terms of how long the virus will continue - and for all intents and purposes, SARS-CoV2 virus, covid-19, is likely to be with us during the course of our lifetimes,

Feb 1, 2021 Over 17 million people near Beijing are under stay-at-home because of a USA variant that has evolved here, in addition to the UK variant

A major clinical trial in Canada shows that an inexpensive anti-inflammatory drug
colchicine can significantly reduce risk of complications and death from COVID19.

North Carolina reports with nearly no testing, 195 cases of B.1.1.7 reported in 21 states as of Jan. 22.

The U.S. CDC forecasts U.K. variant which is roughly 50% more transmissible, will outcompete the original strain of the virus and become dominant across the country by late March.
Almost 700 cases involving new strains have been diagnosed already arriving in most states

Anonymous said...

Now that is is April 24, 2021 - mainstream media says that Covid is out of control in India - what is ACTUALLY going on in India???